FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an isolated antibody against BTN3A, a pharmaceutical composition that mediates the activation of Vγ9Vδ2 T-cells, which includes an anti-BTN3A antibody, an expression vector for recombinant production of an anti-BTN3A antibody in a host cell, a host cell for recombinant production of an anti-BTN3A antibody, comprising an expression vector, and a method of producing an anti-BTN3A antibody, including culturing a host cell to express the said antibody host cell and isolation of the antibody. The isolated anti-BTN3A antibody contains the heavy chain sequence of SEQ ID NO: 1 and a light chain sequence selected from the sequences of SEQ ID NO: 2 and SEQ ID NO: 3.
EFFECT: invention expands the arsenal of agents that bind to BTN3A-H4.
15 cl, 5 dwg, 28 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| RECOMBINANT YEAST CELLS PRODUCING POLYLACTIC ACID AND THEIR USE | 2016 |
|
RU2758138C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE | 2017 |
|
RU2780410C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
